好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Immune-mediated rippling muscle disease, associated neoplasia and response to therapy.
Neuromuscular and Clinical Neurophysiology (EMG)
S58 - Therapeutics in Neuromuscular Disorders (1:22 PM-1:33 PM)
003

RMD is a rare muscle hyper-excitability disorder, characterized by stiffness, cramps, mounding and rippling of the muscle. RMD can be hereditary (hRMD) or immune-mediated (iRMD). The mosaic pattern of sarcolemma caveolin-3 expression in iRMD distinguishes it from hRMD.

To describe the features of a series of patients with iRMD.

Retrospective review of clinical and investigatory findings of RMD patients presenting to our institution in the past decade.

We identified 6 patients with iRMD and one with hRMD. IRMD patients presented with: muscle rippling and cramps (4) and cramps followed by rippling (2). Coexisting autoimmune diseases were present in 3, manifesting within 6 months of iRMD symptom-onset in 2. Two patients developed urticaria around iRMD symptom-onset.  CK was elevated in 5 patients (range 336 – 2600 U/L). AChR Antibodies were positive in 3 patients, associated with clinical myasthenia and an abnormal SFEMG in 1 patient; 4 patients had anti-striated muscle antibodies without thymoma. EMG showed myopathic changes in all patients accompanied by fibrillation potentials or increased insertional activity in 4, most commonly in paraspinal and rippling muscles. Rippling was electrophysiologically active in 3 patients and silent in 1. Muscle biopsy revealed an active myopathy in 4 patients with perimysial inflammatory infiltrates in 3. Caveolin-3 expression was patchy in all iRMD muscle biopsies, and accompanied by reduced dysferlin expression in 2/3. One patient had a history of breast cancer. Four patients received immunotherapy, including IVIG (3), PLEX (1), and steroids (2). Post-treatment data was available in 3 patients: one patient had symptom resolution, 1 marked improvement and 1 no benefit.

iRMD was more frequent than hRMD. All iRMD patients had myopathic EMG changes; rippling was electrically active in 3/4. An inflammatory myopathy was present in half. Differentiation from hRMD is essential for proper pharmacological treatment as 2 of 3 improved on immunotherapy.    

Authors/Disclosures
James D. Triplett, MBBS (Concord Hospital)
PRESENTER
Dr. Triplett has nothing to disclose.
Teerin Liewluck, MD, FAAN (Department of Neurology, Mayo Clinic) Dr. Liewluck has nothing to disclose.
William J. Litchy, MD, FAAN Dr. Litchy has nothing to disclose.
Margherita Milone, MD, FAAN (Mayo Clinic) Dr. Milone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Milone has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Genetics, AAN. The institution of Dr. Milone has received research support from Mayo Clinic, CCaTS-CBD. The institution of Dr. Milone has received research support from Mayo Clinic, SGP Award. The institution of Dr. Milone has received research support from MDA for Care Center grant. The institution of Dr. Milone has received research support from Regenerative medicine Minnesota.